https://www.avient.com/sites/default/files/2021-07/mevopur-needle-hub-1-page-case-study.pdf
NEEDLE HUB
MANUFACTURER
N E E D L E H U B C O L O R S
• RAL and Pantone® colors available in palette to align with
ISO 6009 color standard
• Opaque and transparent polypropylene selections
available in both masterbatch and ready-to-use precolors
• Raw materials pre-tested to ISO 10993 and USP Class VI
medical device guidelines
• Certified formulations available globally
• Provided RAL and Pantone colors as
required
• Developed custom polypropylene
formulations to meet specific opacities
• Offered pre-tested raw materials and
produced in an ISO 13485 certified site,
minimizing risk across the value chain
• Provided global formulations transferrable
from our three ISO 13485 certified facilities
Mevopur™ Healthcare Colors
KEY REQUIREMENTS
WHY AVIENT?
https://www.avient.com/sites/default/files/2020-07/case-study-one-pager-versalloy-infusion-adapter-port.pdf
M E D I C A L E Q U I P M E N T
M A N U FA C T U R E R
C L O S E D S Y S T E M D R U G
T R A N S F E R D E V I C E
• A new material for a seal inside the next generation of
closed system drug transfer device
• Compliance with stringent regulatory standards:
• Biocompatibility to ISO10993
• USP VI compliance
• Provided regulatory support services and
expertise throughout extensive medical
approval process
• Provided a custom formulation compliant with
the highest healthcare regulatory standards
• Enabled material to be manufactured and
shipped globally
Custom Versalloy™ HC 9220-90 Formulation
KEY REQUIREMENTS
WHY AVIENT?
https://www.avient.com/sites/default/files/2020-07/case-study-one-pager-dynaflex-medical-face-mask.pdf
E U R O P E A N M E D I C A L
D E V I C E M A N U FA C T U R E R
F A C E M A S K V E N T I L A T I O N
V A L V E
• ISO 9001 and USP VI compliant
• Compatible with overmolding onto PP
• Translucent and highly colorable
• Soft touch
• Provided valuable regulatory support and
documentation, enabling faster internal trials and
material qualification for this customer
• Worked together with customer to select the best
material from a broad portfolio of medical TPE
grades
• Trusted as a polymer supplier for multiple
healthcare applications
Dynaflex™ G2711 Thermoplastic Elastomer
KEY REQUIREMENTS
WHY AVIENT?
https://www.avient.com/sites/default/files/2020-10/investing-in-avient.pdf
We partner with Brand Owners / OEMs, processors and
assemblers to enable their goals in applications like packaging,
healthcare, consumer goods, transportation, wire & cable,
building & construction and textiles.
We will do so though our investments and focus on
sustainable solutions for high-growth markets, including healthcare,
consumer, packaging and composites/5G.
SEGMENT HIGHLIGHTS
Packaging
37%
Consumer
22%
Healthcare
8%
Industrial
14%
Building &
Construction
8%
Transportation
6%
Wire & Cable
3%
Electrical &
Electronics
2%
C O L O R , A D D I T I V E S & I N K S
2 0 2 0 P F R E V E N U E | $ 2 . 0 B I L L I O N
$9
$310
2.0%
15.5%
2020 figures Pro forma estimates for acquisition of the Clariant Masterbatch business
US & Canada
32%
Europe
39%
Asia
23%
Latin America
6%
END MARKET REGION EBITDA DOLLAR & MARGIN
EXPANSION
24
US & Canada
59%
Europe
23%
Asia
18%
Consumer
23%
Healthcare
10%
Packaging
6%
Wire & Cable(1)
25%
Electrical &
Electronics
14%
Industrial
10%
Transportation
10%
Building &
Construction
2%
S P E C I A L T Y E N G I N E E R E D M A T E R I A L S
2 0 2 0 E R E V E N U E | $ 6 8 5 M I L L I O N
0.9%
16.8%
END MARKET REGION EBITDA DOLLAR & MARGIN
EXPANSION
25
(1) Approximately 50% of Wire and Cable sales are associated with Fiber Optic Cabling
Healthcare
30%
Consumer
24%Packaging
3%
Industrial
19%
Transportation
15%
Electrical &
Electronics
4%
Building &
Construction
4%
Wire & Cable
1%
US & Canada
79%
Asia
2%
Latin
America
19%
END MARKET REGION EBITDA DOLLAR & MARGIN
EXPANSION
D I S T R I B U T I O N
2 0 2 0 E R E V E N U E | $ 1 . 0 5 B I L L I O N
$20
$65
2.9%
6.2%
K E Y S U P P L I E R S
26
AMERICAS EUROPE ASIA
Consumer
26%
Healthcare
19%
Packaging
13%
Industrial
16%
Wire & Cable
7%
Building &
Construction
5%
Electrical &
Electronics
4%
Packaging
35%
Consumer
14%Healthcare
6%
Industrial
17%
Wire & Cable
10%
Building &
Construction
8%
Electrical &
Electronics
3%
Packaging
32%
Consumer
26%
Healthcare
12%
Industrial
7%
Wire & Cable
6%
Building &
Construction
4%
Electrical &
Electronics
9%
Transportation
10%
Transportation
7%
Transportation
4%
2020 figures Pro forma estimates for acquisition of the Clariant Masterbatch business
T O T A L C O M PA N Y R E G I O N A L S A L E S
B Y E N D M A R K E T
(58% of sales) (25% of sales) (17% of sales)
27
https://www.avient.com/sites/default/files/2021-05/avnt-first-quarter-2021-earnings-presentation.pdf
This
innovation drives performance and is
reflective of consistent, strategic
investments in our portfolio…and
people.
2020 Pro forma $991 $86
Sustainable Solutions 15 11% 6
Healthcare 28 22% 6
Composites 6 10% 3
Growth in Emerging Regions 44 30% 10
Other 53 10% 7
Sub-total $1,137 15% $118
FX Impact 25 - 2
Synergies - - 11
Incentives, Travel, Other Employee Costs - - (8)
2021 Actual $1,162 17% $123
Q1 2021 ORGANIC SALES AND OPERATING INCOME
( T O TA L C O M PA N Y )
7
(1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition
Sales Growth Rate
Adjusted
Operating
Income$ millions
(1)
8
Electrical &
Electronics
Building &
Construction
Wire & Cable Transportation Industrial Healthcare Packaging Consumer
Q1 2020PF Q1 2021
(1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition
(2) Financial information is presented on a constant currency basis
(1,2)
(42% of total revenue)
(58% of total revenue)
Q1 END MARKET SALES PERFORMANCE
+17%
+14% +8%
+10%
+8% +22%
+5%
+24%
Q 2 A N D F U L L Y E A R
2 0 2 1 O U T L O O K
$69
$112
2020PF 2021E
$0.42
$0.80
2020PF 2021E
ORGANIC GROWTH PROJECTIONS – Q2
( T O TA L C O M PA N Y )
10
Sales Adjusted Operating Income
$870
$1,100
2020PF 2021E
+ 26%
Adjusted EPS
+ 62% + 90%
(in millions) (in millions)
(1) (1) (1)
(1) Financial information is pro forma to include a full year of Clariant Masterbatch business acquisition
FULL YEAR GUIDANCE INCREASED
11
Sales Adj.
We will deliver for our stakeholders through multiple value creation levers—many of
which are unique to Avient:
o Demand for sustainable solutions, healthcare, and composites, together with Clariant
Masterbatch revenue synergies, that will drive 2021 revenue growth of 14% and long-term
growth in excess of GDP
o Clariant Masterbatch cost synergy capture will result in significant near-term benefit
In addition, we remain committed to increasing annual dividends in line with earnings growth and
opportunistically buying back shares, all while remaining modestly levered.
APPENDIX
Performance
Additives
15%
Pigments
15%
TiO2
12%
Dyestuffs
4%Polyethylene
10%
Nylon
5%
Polypropylene
4%
Other Raw
Materials
29%
Styrenic Block
Copolymer
6%
~1/3 hydrocarbon based
(Grey shaded materials are hydrocarbon based,
includes portion of “Other Raw Materials”)
Non-hydrocarbon
based materials
23
• Exiting 2020, the majority of hydrocarbon based raw
material markets were experiencing price inflation
and tight inventory
• Winter Storm Uri in the Gulf Coast caused further
stress on the situation for 2021
• Raw materials most impacted include polyethylene,
polypropylene and nylon
• We purchase over 8,000 different raw materials to
formulate our customized solutions and unique
specifications
Annual Purchases
RAW MATERIAL UPDATE
Based on 2020 pro forma purchases, excludes Distribution
SEGMENT DATA
U.S. & Canada
50%
EMEA
26%
Asia
16%
Latin America
8%
2020 SEGMENT, END MARKET AND GEOGRAPHY
25
GEOGRAPHY REVENUESEGMENT FINANCIALS
Consumer
23%
Packaging
21%Industrial
15%
Wire & Cable
6%
Building &
Construction
6%
Electrical &
Electronics
4%
END MARKET REVENUE
Transportation
10%
Healthcare
15%
All data reflects 2020 Pro forma for acquisition of the Clariant Masterbatch business.
(1) The total company sales and EBITDA of $3,783M and $457M, respectively, include intercompany sales eliminations and corporate costs
$2,043M
$331M
$709M
$124M
$1,110M
$70M
Sales EBITDA
Distribution
Specialty Engineered Materials
Color Additives and Inks
$457M$3,783M
(1)
Packaging
35%
Consumer
23%
Healthcare
8%
Industrial
14%
Building &
Construction
8%
Transportation
7%
Wire & Cable
3%
Electrical &
Electronics
2%
C O L O R , A D D I T I V E S & I N K S
2 0 2 0 P F R E V E N U E | $ 2 . 0 B I L L I O N
US & Canada
31%
EMEA
40%
Asia
22%
Latin America
7%
END MARKET REGION
26
2020 figures Pro forma for acquisition of the Clariant Masterbatch business
S P E C I A L T Y E N G I N E E R E D M A T E R I A L S
Consumer
24%
Healthcare
10%
Packaging
6%
Wire & Cable(1)
24%
Electrical &
Electronics
13%
Transportation
11%
Industrial
10%
Building &
Construction
2%
2 0 2 0 R E V E N U E | $ 7 0 9 M I L L I O N
END MARKET
US & Canada
58%
EMEA
23%
Asia
19%
REGION
27
(1) Approximately 50% of Wire and Cable sales are associated with Fiber Optic Cabling
D I S T R I B U T I O N
2 0 2 0 R E V E N U E | $ 1 . 1 B I L L I O N
Healthcare
29%
Consumer
25%
Packaging
2%
Industrial
20%
Transportation
14%
Electrical &
Electronics
5%
Building &
Construction
4%
Wire & Cable
1%
US & Canada
82%
Asia
3%
Latin
America
15%
END MARKET REGION
K E Y S U P P L I E R S
28
T O T A L C O M PA N Y R E G I O N A L S A L E S
B Y E N D M A R K E T
Packaging
32%
Consumer
27%
Healthcare
12%
Industrial
6%
Wire & Cable
6%
Building &
Construction
4%
Electrical &
Electronics
9%
Asia
(16% of sales)
Transportation
4%
Packaging
34%
Consumer
16%Healthcare
5%
Industrial
17%
Wire & Cable
10%
Building &
Construction
8%
Electrical &
Electronics
3%
EMEA
(26% of sales)
Transportation
7%
2020 figures Pro forma for acquisition of the Clariant Masterbatch business
29
Transportation
10%
Consumer
26%
Healthcare
19%
Packaging
13%
Industrial
16%
Wire & Cable
7%
Building &
Construction
5%
Electrical &
Electronics
4%
US &
Canada
(50% of sales)
Packaging
45%
Consumer
29%
Healthcare
6%
Industrial
8%
Building &
Construction
3%
Electrical &
Electronics
2% Wire & Cable
1%
LATAM
(8% of sales)
Transportation
6%
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(Dollars in millions, except for per share data)
Three Months Ended
March 31, 2021
Reconciliation to Condensed Consolidated Statements of Income
GAAP
Results
Special
Items
Adjusted
Results
Income from continuing operations before income taxes $ 102.6 $ 2.4 $ 105.0
Income tax expense - GAAP (22.9) — (22.9)
Income tax impact of special items — (0.9) (0.9)
Tax adjustments — 1.1 1.1
Net income attributable to noncontrolling interests (0.4) — (0.4)
Net income from continuing operations attributable to Avient shareholders $ 79.3 $ 2.6 $ 81.9
Net income / EPS $ 0.86 0.03 $ 0.89
Weighted-average diluted shares 92.2 92.2 92.2
Reconciliation to Consolidated Statements of Income
Three Months Ended
March 31, 2021
Operating income - GAAP $ 120.4
Special items in operating income 2.4
Adjusted Operating income $ 122.8
1
Business Segment Operations
Three Months Ended
March 31,
Year Ended
December 31,
2021 2020 2020 2019 2018
Sales:
Color, Additives and Inks $ 609.3 $ 256.5 $ 1,502.9 $ 1,003.8 $ 1,046.5
Specialty Engineered Materials 216.5 185.3 708.8 745.7 645.8
Distribution 362.7 289.5 1,110.3 1,192.2 1,265.4
Corporate and eliminations (26.2) (19.8) (79.9) (79.0) (76.7)
Sales $ 1,162.3 $ 711.5 $ 3,242.1 $ 2,862.7 $ 2,881.0
Gross margin:
Color, Additives and Inks $ 197.5 $ 89.4 $ 484.4 $ 338.4 $ 353.4
Specialty Engineered Materials 64.7 52.6 207.6 200.2 171.7
Distribution 39.3 33.6 124.0 132.1 125.8
Corporate and eliminations 0.9 (4.1) (31.7) (13.5) (26.1)
Gross margin $ 302.4 $ 171.5 $ 784.3 $ 657.2 $ 624.8
Selling and administrative expense:
Color, Additives and Inks $ 108.7 $ 48.9 $ 303.6 $ 191.0 $ 194.9
Specialty Engineered Materials 30.5 30.3 113.2 116.5 99.4
Distribution 15.3 14.2 54.5 56.7 54.3
Corporate and eliminations 27.5 25.3 123.7 136.2 97.6
Selling and administrative expense $ 182.0 $ 118.7 $ 595.0 $ 500.4 $ 446.2
Operating income:
Color, Additives and Inks $ 88.8 $ 40.5 $ 180.8 $ 147.4 $ 158.5
Specialty Engineered Materials 34.2 22.3 94.4 83.7 72.3
Distribution 24.0 19.4 69.5 75.4 71.5
Corporate and eliminations (26.6) (29.4) (155.4) (149.7) (123.7)
Operating income $ 120.4 $ 52.8 $ 189.3 $ 156.8 $ 178.6
Earnings before interest, taxes, depreciation and
amortization (EBITDA):
Color, Additives and Inks $ 116.2 $ 51.4 $ 255.9 $ 190.1 $ 202.8
Specialty Engineered Materials 42.0 29.8 124.4 113.2 95.5
Distribution 24.2 19.5 70.2 75.9 72.2
Corporate and eliminations (24.9) (28.0) (146.2) (144.3) (119.3)
Other income, net 1.5 1.6 24.3 12.1 (12.9)
EBITDA $ 159.0 $ 74.3 $ 328.6 $ 247.0 $ 238.3
EBITDA as a % of Sales:
Color, Additives and Inks 19.1 % 20.0 % 17.0 % 18.9 % 19.4 %
Specialty Engineered Materials 19.4 % 16.1 % 17.6 % 15.2 % 14.8 %
Distribution 6.7 % 6.7 % 6.3 % 6.4 % 5.7 %
2
Reconciliation of Pro Forma EBITDA - Color,
Additives and Inks
Three Months Ended
March 31,
Year Ended
December 31,
2021 2020 2020 2019 2018
Sales:
Color, Additives and Inks $ 609.3 $ 256.5 $ 1,502.9 $ 1,003.8 $ 1,046.5
Clariant MB pro forma adjustments(1) — 279.4 540.4 1,118.6 1,209.8
Pro forma sales $ 609.3 $ 535.9 $ 2,043.3 $ 2,122.4 $ 2,256.3
Operating income:
Color, Additives and Inks $ 88.8 $ 40.5 $ 180.8 $ 147.4 $ 158.5
Clariant MB pro forma adjustments(1) — 23.0 45.0 72.9 80.3
Pro forma operating income $ 88.8 $ 63.5 $ 225.8 $ 220.3 $ 238.8
Depreciation & amortization:
Color, Additives and Inks $ 27.4 $ 10.9 $ 75.1 $ 42.7 $ 44.3
Clariant MB pro forma adjustments(1) — 15.1 30.1 60.3 61.2
Pro forma depreciation & amortization $ 27.4 $ 26.0 $ 105.2 $ 103.0 $ 105.5
Earnings Before Interest, Taxes, Depreciation
and Amortization (EBITDA):
Color, Additives and Inks $ 116.2 $ 51.4 $ 255.9 $ 190.1 $ 202.8
Clariant MB pro forma adjustments(1) — 38.1 75.1 133.2 141.5
Pro forma EBITDA $ 116.2 $ 89.5 $ 331.0 $ 323.3 $ 344.3
Pro forma EBITDA as a % of Sales 19.1 % 16.7 % 16.2 % 15.2 % 15.3 %
Three Months Ended
March 31, 2020
Reconciliation of Pro Forma Adjusted Earnings per
Share Avient
Special
Items
Adjusted
Avient
Clariant MB
Pro Forma
Adjustments(1)
Pro Forma
Adjusted
Avient
Sales $ 711.5 $ — $ 711.5 $ 279.4 $ 990.9
Operating income 52.8 9.7 62.5 23.0 85.5
Interest expense, net (9.4) — (9.4) (12.8) (22.2)
Other income, net 1.6 (0.1) 1.5 — 1.5
Income taxes (11.9) (1.0) (12.9) (2.4) (15.3)
Net income from continuing operations attributable to
Avient shareholders $ 33.1 $ 8.6 $ 41.7 $ 7.8 $ 49.5
Weighted average diluted shares 86.7
Impact to diluted shares from January 2020 equity offering 6.1
Weighted average diluted shares 92.8
EPS $ 0.53
(1) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition
3
Three Months Ended
June 30, 2020
Reconciliation of Pro Forma Adjusted Earnings per
Share Avient
Special
Items
Adjusted
Avient
Clariant MB
Pro Forma
Adjustments(2)
Pro
Forma
Adjusted
Avient
Sales $ 609.1 $ — $ 609.1 $ 261.1 $ 870.2
Operating income $ 38.0 $ 9.0 $ 47.0 $ 22.0 $ 69.0
Interest expense, net (16.2) — (16.2) (5.3) (21.5)
Other income, net 9.5 (0.3) 9.2 — 9.2
Income taxes (7.9) 0.7 (7.2) (3.8) (11.0)
Net income attributable to non controlling interests
(0.4) — (0.4) — (0.4)
Net income from continuing operations attributable to
Avient shareholders $ 23.0 $ 9.4 $ 32.4 $ 12.9 $ 45.3
Weighted average diluted shares 91.8
Impact to diluted shares from January 2020 equity offering 15.3
Pro forma weighted average diluted shares 107.1
Pro forma adjusted EPS $ 0.42
(2) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition
Year Ended
December 31,
Reconciliation to Adjusted EBITDA 2020 2019 2018
Net income from continuing operations – GAAP $ 133.8 $ 75.7 $ 87.4
Income tax expense 5.2 33.7 14.4
Interest expense 74.6 59.5 62.8
Debt extinguishment cost — — 1.1
Depreciation and amortization from continuing operations 115.0 78.1 72.6
EBITDA $ 328.6 $ 247.0 $ 238.3
Special items, before tax 66.2 61.7 59.5
Interest expense included in special items (10.1) — —
Accelerated depreciation included in special items (3.2) — (3.0)
Adjusted EBITDA $ 381.6 $ 308.7 $ 294.8
4
Year Ended
December 31, 2020
Reconciliation of Pro Forma Adjusted
Earnings per Share Avient
Special
Items
Adjusted
Avient
Clariant MB
Pro Forma
Adjustments(3)
Pro Forma
Adjusted
Avient
Sales $ 3,242.1 $ — $ 3,242.1 $ 540.4 $ 3,782.5
Operating income $ 189.3 $ 73.7 $ 263.0 $ 45.0 $ 308.0
Interest expense, net (74.6) 10.1 (64.5) (18.1) (82.6)
Other income, net 24.3 (17.6) 6.7 — 6.7
Income taxes (5.2) (41.4) (46.6) (6.2) (52.8)
Net income attributable to noncontrolling
interests (1.8) — (1.8) — (1.8)
Net income from continuing operations
attributable to Avient shareholders $ 132.0 $ 24.8 $ 156.8 $ 20.7 $ 177.5
Weighted average diluted shares 90.6
Impact to diluted shares from January 2020 equity offering 1.5
Pro forma weighted average diluted shares 92.1
Pro forma adjusted EPS $ 1.93
Reconciliation of Pro Forma Adjusted
EBITDA from continuing operations
Operating income and other income, net $ 213.6 $ — $ 56.1 $ 269.7 $ 45.0 $ — $ 314.7
Depreciation and amortization 115.0 (3.2) 111.8 30.1 141.9
EBITDA from continuing operations $ 328.6 $ 52.9 $ 381.5 $ 75.1 $ 456.6
Year Ended
December 31, 2019
Reconciliation of Pro Forma Adjusted
Earnings per Share Avient
Special
Items
Adjusted
Avient
Clariant MB
Pro Forma
Adjustments(1)
Pro Forma
Adjusted
Avient
Sales $ 2,862.7 $ — $ 2,862.7 $ 1,118.6 $ 3,981.3
Operating income $ 156.8 $ 71.7 $ 228.5 $ 72.9 $ 301.4
Interest expense, net (59.5) — (59.5) (33.4) (92.9)
Other income, net 12.1 (10.0) 2.1 — 2.1
Income taxes (33.7) (5.9) (39.6) (9.1) (48.7)
Net income attributable to noncontrolling
interests (0.2) — (0.2) — (0.2)
Net income from continuing operations
attributable to Avient shareholders $ 75.5 $ 55.8 $ 131.3 $ 30.4 $ 161.7
Weighted average diluted shares 77.7
Impact to diluted shares from January 2020 equity offering 15.3
Pro forma weighted average diluted shares 93.0
Pro forma adjusted EPS $ 1.74
Reconciliation of Pro Forma Adjusted
EBITDA from continuing operations
Operating income and other income, net $ 168.9 $ — $ 61.7 $ 230.6 $ 72.9 $ — $ 303.5
Depreciation and amortization 78.1 — 78.1 60.3 138.4
EBITDA from continuing operations $ 247.0 $ 61.7 $ 308.7 $ 133.2 $ 441.9
(3) - Pro forma adjustments for the periods prior to the acquisition date (July 1, 2020) and to give effects of the financing for the acquisition
5
AVNT First Quarter 2021 Earnings Presentation no recs.pdf
AVNT First Quarter 2021 Earnings Presentation.pdf
AVNT First Quarter 2021 Earnings Presentation.pdf
AVNT First Quarter 2021 Earnings Presentation.pdf
4.29 127pm Q1 21 IR Deck Version non-GAAP Recs (002).pdf
https://www.avient.com/sites/default/files/2020-11/investing-in-avient_0.pdf
We partner with Brand Owners / OEMs, processors and
assemblers to enable their goals in applications like packaging,
healthcare, consumer goods, transportation, wire & cable,
building & construction and textiles.
We will do so though our investments and focus on
sustainable solutions for high-growth markets, including healthcare,
consumer, packaging and composites/5G.
SEGMENT HIGHLIGHTS
Packaging
37%
Consumer
22%
Healthcare
8%
Industrial
14%
Building &
Construction
8%
Transportation
6%
Wire & Cable
3%
Electrical &
Electronics
2%
C O L O R , A D D I T I V E S & I N K S
2 0 2 0 P F R E V E N U E | $ 2 . 0 B I L L I O N
$9
$320
2005 2020PF
2.0%
15.9%
2020 figures Pro forma estimates for acquisition of the Clariant Masterbatch business
US & Canada
32%
Europe
39%
Asia
23%
Latin America
6%
END MARKET REGION EBITDA DOLLAR & MARGIN
EXPANSION
24
$5
$120
2005 2020E
US & Canada
59%
Europe
23%
Asia
18%
Consumer
23%
Healthcare
10%
Packaging
6%
Wire & Cable(1)
25%
Electrical &
Electronics
14%
Industrial
10%
Transportation
10%
Building &
Construction
2%
S P E C I A L T Y E N G I N E E R E D M A T E R I A L S
2 0 2 0 E R E V E N U E | $ 7 0 0 M I L L I O N
0.9%
17.1%
END MARKET REGION EBITDA DOLLAR & MARGIN
EXPANSION
25
(1) Approximately 50% of Wire and Cable sales are associated with Fiber Optic Cabling
Healthcare
30%
Consumer
24%Packaging
3%
Industrial
19%
Transportation
15%
Electrical &
Electronics
4%
Building &
Construction
4%
Wire & Cable
1%
US & Canada
79%
Asia
2%
Latin
America
19%
END MARKET REGION EBITDA DOLLAR & MARGIN
EXPANSION
D I S T R I B U T I O N
2 0 2 0 E R E V E N U E | $ 1 . 1 B I L L I O N
$20
$70
2005 2020E
2.9%
6.3%
K E Y S U P P L I E R S
26
AMERICAS EUROPE ASIA
Consumer
26%
Healthcare
19%
Packaging
13%
Industrial
16%
Wire & Cable
7%
Building &
Construction
5%
Electrical &
Electronics
4%
Packaging
35%
Consumer
14%Healthcare
6%
Industrial
17%
Wire & Cable
10%
Building &
Construction
8%
Electrical &
Electronics
3%
Packaging
32%
Consumer
26%
Healthcare
12%
Industrial
7%
Wire & Cable
6%
Building &
Construction
4%
Electrical &
Electronics
9%
Transportation
10%
Transportation
7%
Transportation
4%
2020 figures Pro forma estimates for acquisition of the Clariant Masterbatch business
T O T A L C O M PA N Y R E G I O N A L S A L E S
B Y E N D M A R K E T
(58% of sales) (25% of sales) (17% of sales)
27
https://www.avient.com/sites/default/files/2023-08/AVNT August IR Presentation w NonGAAP Recs%5B40%5D.pdf
&
Canada
EMEA
Asia
Latin America
64%
36%
Specialty
Engineered
Materials
Color
Additives
and Inks
40%
37%
18%
5%
6%
8%
24%
20%
10%
15%
9% 4% 4%
Defense
Healthcare
Packaging
Consumer
Building &
Construction
Industrial
Transportation
Energy Telecom
4
C R EAT I N G A WO R L D- C L A SS
S US TA I NA B L E ORG A N I ZAT I ON
1. 6.5% annualized long term sales
growth leveraging sustainable
solutions, composites, healthcare
and emerging regions
2.
We partner with Brand Owners / OEMs, processors and
assemblers to enable their goals in applications like packaging,
healthcare, consumer goods, transportation, wire & cable,
building & construction and textiles.
Avient 2011 and 2018 valuations reflect trailing 12 months EBITDA at December 31 of the respective years.
28
EV / 2023E EBITDA
Historic Multiple
6.5
8.3
9.5
13.8
12.7 12.6
11.3
8.7
18.6
16.5
10.1 10.0 9.7 9.5 9.4
8.7
A
vi
e
n
t
(2
0
1
1
)
A
vi
e
n
t
(2
0
1
8
)
A
vi
e
n
t
(2
0
2
3
)
R
P
M
P
P
G
A
V
Y
K
W
R
F
U
L
E
C
L
H
X
L
F
M
C
A
S
H
S
C
L
H
U
N
C
E
E
M
N
Avient Specialty
Formulators
Other Specialty /
Chemical Companies
SEGMENT DATA
U.S. & Canada
40%
EMEA
37%
Asia
18%
Latin America
5%
2022 PRO FORMA SEGMENT, END MARKET AND GEOGRAPHY
GEOGRAPHY REVENUESEGMENT FINANCIALS
Consumer
20%
Packaging
24%
Industrial
15%
Building and
Construction
10%
Telecommunications
4%
Energy
4%
Defense
6%
END MARKET REVENUE
$2,355M $402M
$1,300M $272M
Sales EBITDA
Specialty Engineered Materials
Color Additives and Inks
$592M$3,653M
(1)
Transportation
9%
Healthcare
8%
30
(1) Total company sales and adjusted EBITDA of $3,653M and $592M, respectively, include intercompany sales eliminations and corporate costs
2 0 2 2 R E V E N U E | $ 2 . 4 B I L L I O N
US & Canada
34%
EMEA
38%
Asia
20%
Latin America
8%
END MARKET REGION
31
Packaging
34%
Consumer
21%
Healthcare
8%
Industrial
15%
Transportation
8%
Building &
Construction
11%
Telecommunications
1% Energy
2%
COLOR , AD DI TI VES & INKS
2 0 2 2 P R O F O R M A R E V E N U E | $ 1 . 3 B I L L I O N
US & Canada
52%
EMEA
35%
Asia
13%
32
Packaging
5%
Consumer
19%
Healthcare
8%Industrial
16%
Transportation
10%
Telecommunications
10%
Energy
9% Defense
15%
Building &
Construction
8%
END MARKET REGION
SPEC IA LTY ENGI NEER ED MATERI ALS
Packaging
32%
Consumer
27%
Healthcare
8%
Industrial
14%
Building &
Construction
5%
Telecommunications
3%
Energy
1% Defense
1%
Asia
(18% of sales)
Transportation
9%
2 0 2 2 P R O F O R M A AV I E N T R E G I O N A L S A L E S
Packaging
27%
Consumer
14%
Healthcare
5%
Industrial
17%
Building &
Construction
10%
Energy
5%
Defense
8%
EMEA
(37% of sales)Transportation
11%
Packaging
13%
Consumer
24%
Healthcare
12%
Industrial
15%
Building &
Construction
13%
Energy
5%
Defense
5%
US &
Canada
(40% of sales)
Transportation
7%
Packaging
56%
Consumer
23%
Healthcare
4%
Industrial
7%
Building &
Construction
4%
Telecommunications
1%
LATAM
(5% of sales)
Transportation
5%
Telecommunications
3%
Telecommunications
6%
33
B Y E N D M A R K E T
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(Dollars in millions, except for per share data)
Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders
and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special
items, to assess performance and facilitate comparability of results.
https://www.avient.com/sites/default/files/2023-03/AVNT Q2 2022 Earnings Presentation - Website Version.pdf
EPS (ex Amort) 3.96$ 0.13$ 4.09$ (0.58)$ 3.51$
Pro Forma Leverage (12/31/2022E)
Net Debt / Adjusted EBITDA 1.6x 3.4x 2.8x
Forecast Dyneema
Forecast +
Dyneema
Sale of
Distribution
Pro Forma
2022
TWO-YEAR LEVER AGE MODEL
16
3.5x
2.7x
1.6x
2.8x
2.4x
2.0x
2019PF 2020PF 2022E 2022PF 2023E 2024E
Dyneema® AcquisitionClariant Color Acquisition
(1) Pro forma for the acquisition of the Clariant Color business
(2) Pro forma for the acquisition of Dyneema® and potential divestiture of
Distribution, including repayment of senior notes due 2023 and Term Loan
(1) (1) (2)
OUR SPEC IA LTY JOURNEY C ONTINUES
17
• Dyneema® brings leading technology and brand with
the World’s Strongest Fiber™, deep history of
application development and strong
management team focused on specialty
applications
• Dyneema® transaction is aligned with our previously
stated acquisition goal of expanding our composites
and fiber capabilities
• Similar to our other technology expansion
acquisitions, Dyneema® allows us to leverage our
invest-to-grow strategy
• The possible sale of our Distribution business also
presents potential benefits with respect to leverage
and EBITDA margins
7%
46%
66%
86%
100%
0%
20%
40%
60%
80%
100%
2005 2010 2015 2021 2022 PF
%
o
f A
d
ju
st
e
d
E
B
IT
D
A
(1
)
JVs Distribution Performance Products & Solutions Specialty
(1) Adjusted EBITDA is EBITDA excluding corporate costs and special items
(2) Pro forma for the acquisition of Dyneema® and potential divestiture of Distribution
(2)
Healthcare
4%
Packaging
8%
Consumer
10%
Building &
Construction
43%
Industrial
15%
Transportation
14%
Energy
4%
Telecom.
2%
2006 2022 Pro forma
Healthcare
8%
Packaging
23%
Consumer
21%
Building &
Construction
10%
Industrial
15%
Transportation
9%
Energy
4%
Telecom.
4%
Defense
6%
END MAR KET TR ANSF OR MATION TO LESS
CYCLI CAL INDUSTRI ES
( W I T H D Y N E E M A , E X .
D I S T R I B U T I O N )
18
END-MARKET F OCUS F OR
NEW I NNOVATION
Semiconductors Robotics Healthcare
Interconnected disruptive markets with massive innovation needs
19
APPENDIX
Performance
Additives
15%
Pigments
13%
TiO2
11%
Dyestuffs
3%Polyethylene
12%
Nylon
6%
Polypropylene
5%
Other Raw
Materials
30%
Styrenic Block
Copolymer
5%
~40% hydrocarbon based
(Grey shaded materials are hydrocarbon based,
includes portion of “Other Raw Materials”)
Non-hydrocarbon
based materials
22
• Significant raw material price inflation and
tight inventory continued in Q2 2022,
although at a slightly lesser rate compared
to the prior quarter
o For Q2 2022, the average cost of key
hydrocarbon based materials was up 15%,
roughly the same as the average cost of non-
hydrocarbon based materials
Annual Purchases
RAW MATERIAL AND SUPPLY CHAIN UPDATE
Based on 2021 purchases, excludes Distribution business
SEGMENT DATA
U.S. & Canada
50%
EMEA
25%
Asia
16%
Latin America
9%
2021 SEGMENT, END MARKET AND GEOGRAPHY
GEOGRAPHY REVENUESEGMENT FINANCIALS
Consumer
23%
Packaging
19%
Industrial
16%
Building and
Construction
10%
Telecommunications
4%
Energy
2%
END MARKET REVENUE
(1) Total company sales and adjusted EBITDA of $4,819M and $581M, respectively, include intercompany sales eliminations and corporate costs
$2,402M
$409M
$919M
$164M
$1,631M
$94M
Sales EBITDA
Distribution
Specialty Engineered Materials
Color Additives and Inks
$581M$4,819M
(1)
Transportation
11%
Healthcare
15%
24
Packaging
34%
Consumer
21%
Healthcare
8%
Industrial
16%
Building &
Construction
10%
Transportation
9%
Energy
1% Telecommunications
1%
C O L O R , A D D I T I V E S & I N K S
2 0 2 1 R E V E N U E | $ 2 . 4 B I L L I O N
US & Canada
32%
EMEA
40%
Asia
21%
Latin America
7%
END MARKET REGION
25
All charts reflect 2021 financials
S P E C I A L T Y E N G I N E E R E D M A T E R I A L S
Consumer
27%
Healthcare
10%
Packaging
7%
Telecommunications
16%
Transportation
11%
Industrial
11%
Building &
Construction
11%
Energy
7%
2 0 2 1 R E V E N U E | $ 9 1 9 M I L L I O N
END MARKET
US & Canada
55%
EMEA
25%
Asia
20%
REGION
26
All charts reflect 2021 financials
D I S T R I B U T I O N
Healthcare
26%
Consumer
23%
Packaging
5%
Industrial
20%
Transportation
16%
Building and
Construction
8%
Energy
1%
Telecommunications
1%
US & Canada
80%
Asia
3%
Latin
America
17%
END MARKET REGION
K E Y S U P P L I E R S
2 0 2 1 R E V E N U E | $ 1 . 6 B I L L I O N
27
All charts reflect 2021 financials
T O T A L C O M P A N Y R E G I O N A L S A L E S
B Y E N D M A R K E T
Packaging
30%
Consumer
26%Healthcare
13%
Industrial
14%
Building &
Construction
5%
Telecommunications
2% Energy
2%
Asia
(16% of sales)
Transportation
8%
Packaging
32%
Consumer
13%
Healthcare
5%
Industrial
17%
Building &
Construction
12%
Telecommunications
5%
Energy
4%
EMEA
(25% of sales)
Transportation
12%
28
Consumer
25%
Healthcare
19%
Packaging
10%
Industrial
17%
Building &
Construction
10%
Telecommunications
4%
Energy
2%
US &
Canada
(50% of sales)
Transportation
13%
Packaging
38%
Consumer
33%
Healthcare
8%
Industrial
10%
Building &
Construction
5%
Telecommunications
1%
LATAM
(9% of sales)
Transportation
5%
All charts reflect 2021 financials
Reconciliation of Non-GAAP Financial Measures
(Unaudited)
(Dollars in millions, except for per share data)
Senior management uses comparisons of adjusted net income from continuing operations attributable to Avient shareholders
and diluted adjusted earnings per share (EPS) from continuing operations attributable to Avient shareholders, excluding special
items, to assess performance and facilitate comparability of results.
https://www.avient.com/sites/default/files/2021-04/trilliant-hc-continuous-glucose-monitor-case-study.pdf
HEALTHCARE
DEVICE OEM
C O N T I N U O U S G L U C O S E
M O N I T O R
• Specific color matching for brand alignment and
recognition
• Chemically resistant material to help product last longer
• Single source for materials and color expertise
• Provided a pre-colored solution that met
rigorous application requirements to
improve color consistency between products
• Incorporated scratch & mar resistant
additives for improved durability
• Offered the ability to run small pilot lots
• Met regulatory requirements for USP
Class VI
Trilliant™ HC Thermoplastics
KEY REQUIREMENTS
WHY AVIENT?
https://www.avient.com/products/engineered-polymer-formulations/chemical-corrosion-resistant-formulations/trilliant-hc-healthcare-thermoplastics
https://www.avient.com/sites/default/files/2024-02/Transcend - Tibial Trials Case Study Snapshot.pdf
S U RG I C A L
I N S T RU M E N T O E M
T I B I A L T R I A L S
• Offered in various colors for ease of brand identification
and sizing differentiation
• Able to withstand repeated steam sterilization and
chemical disinfection
• Available in low minimum order quantities (MOQ)
• Delivered a variety of bright, differentiating
color choices
• Maintained excellent mechanical
performance after repeated steam
sterilization and harsh chemical cleaning
• Offered low MOQ with flexible supply
Transcend™ Premier Healthcare Colorants
KEY REQUIREMENTS
WHY AVIENT?
https://www.avient.com/products/polymer-colorants/high-temperature-color-concentrates/colorant-chromatics-transcend-premier-healthcare-colorants